BioVersys AG (FRA:W33) Beta: N/A (As of Jul. 06, 2026)


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.00
View Full Analysis

What is BioVersys AG Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-06), BioVersys AG's Beta is Not available.

BioVersys AG  (FRA:W33) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

BioVersys AG Beta Related Terms

BioVersys AG Beta Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Beta Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Beta
0.00 0.00

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Beta 0.00 0.00 0.00 0.00
FRA:W33
7GF Score
BioVersys AG FRA:W33
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price